The validated French CFAbd‐Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor
The French version of the CFAbd-Score has proved to be reliable and sensitive to capture AS in French-speaking pwCF and to distinguish pwCF from HC. Furthermore, consistent with previous findings, the PROM sensitively detects ETI-related differences in AS of pwCF with and without ETI therapy, and thus can be used in research and clinical routine.
Authors
- Franziska Duckstein (ORCID: https://orcid.org/0000-0002-0938-8502)
- Isabelle Sermet‐Gaudelus (ORCID: https://orcid.org/0000-0001-5537-9482)
- Raphaël Enaud (ORCID: https://orcid.org/0000-0001-9493-5218)
- Carlos Zagoya (ORCID: https://orcid.org/0000-0002-1822-3750)
- Jochen G. Mainz (ORCID: https://orcid.org/0000-0003-3780-7759)
- Anton Barucha
- Jeanne Languepin (ORCID: https://orcid.org/0000-0002-4646-018X)
- Anne Sophie Bonnel
- Pauline Sadrieh
- Nathalie Wizla
- Samira Dabelow
- Ambre Nangui
- Audrey Deelawon
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Université de Bordeaux (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Institut Necker Enfants Malades (FR)
- Institut de Mécanique et d'Ingénierie de Bordeaux (FR)
- Hôpital Jeanne de Flandre (FR)
- Centre Hospitalier Universitaire de Limoges (FR)
- Hôpital André Mignot (FR)
- ERN GUARD-Heart (NL)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
- Centre de Recherche Cardio-Thoracique de Bordeaux (FR)
- Universitätsklinikum Brandenburg an der Havel (DE)
- Brandenburg University of Technology Cottbus-Senftenberg (DE)
Publication Details
- Journal
- Journal of Pediatric Gastroenterology and Nutrition
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1002/jpn3.70244
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Vertex Pharmaceuticals
- PTC Therapeutics